ArticleCold Spring Harbor perspectives in biology2012
Emerging therapeutics targeting mRNA translation.
Article in Cold Spring Harbor perspectives in biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR.Cell death and differentiation · 2026Article
- Article
- Function and Therapeutic Implications of tRNA Derived Small RNAs.Frontiers in molecular biosciences · 2022Review
- Speed Microscopy: High-Speed Single Molecule Tracking and Mapping of Nucleocytoplasmic Transport.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Control of the eIF4E activity: structural insights and pharmacological implications.Cellular and molecular life sciences : CMLS · 2021Review
- The Recurring Roles of Chlorine in Synthetic and Biological Studies of the Lissoclimides.Accounts of chemical research · 2021Review
- Eukaryotic translation initiation factors as promising targets in cancer therapy.Cell communication and signaling : CCS · 2020Review
- Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020Review
- Effective Inhibition ofCancer management and research · 2020Article
- Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery.Frontiers in oncology · 2020Article
- DUBbing Down Translation: The Functional Interaction of Deubiquitinases with the Translational Machinery.Molecular cancer therapeutics · 2019Review
- Role of network-mediated stochasticity in mammalian drug resistance.Nature communications · 2019Article
- The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.Molecular cell · 2019Article
- Article
- Therapeutic Opportunities in Eukaryotic Translation.Cold Spring Harbor perspectives in biology · 2018Review
- Advancements in Host-Based Interventions for Influenza Treatment.Frontiers in immunology · 2018Review
- The Role of the Eukaryotic Translation Initiation Factor 4E (eIF4E) in Neuropsychiatric Disorders.Frontiers in genetics · 2018Review
- Synthesis facilitates an understanding of the structural basis for translation inhibition by the lissoclimides.Nature chemistry · 2017Article
- A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis.European journal of pharmacology · 2017Article
- Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.Genes & development · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A defining feature of many cancers is deregulated translational control. Typically, this occurs at the level of recruitment of the 40S ribosomes to the 5'-cap of cellular messenger RNAs (mRNAs), the rate-limiting step of protein synthesis, which is controlled by the heterotrimeric eukaryotic initiation complex eIF4F. Thus, eIF4F in particular, and translation initiation in general, represent an exploitable vulnerability and unique opportunity for therapeutic intervention in many transformed cells. In this article, we discuss the development, mode of action and biological activity of a number of small-molecule inhibitors that interrupt PI3K/mTOR signaling control of eIF4F assembly, as well as compounds that more directly block eIF4F activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.